Isoflavonoid compounds and methods for the treatment of cancer

1 .- 15 . (canceled) 
     
     
         16 . A compound that is cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol. 
     
     
         17 . A kit comprising a compound that is cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol.
 and   a sealable, plastic infusion bag.   
     
     
         18 . A method of treating cancer in an individual in need of cancer therapy, the method comprising administering to the individual a compound that is cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol. 
     
     
         19 . The method of  claim 18 , wherein the compound increases or induces sensitivity of the cancer to a chemotherapeutic agent, anti-cancer agent, or radiation therapy. 
     
     
         20 . The method of  claim 18 , wherein the cancer has lost sensitivity to a chemotherapeutic agent, anti-cancer agent, or radiation therapy. 
     
     
         21 . The method of  claim 18 , wherein said cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, and cancers of the brain. 
     
     
         22 . The method of  claim 18 , wherein said cancer is human breast cancer or ovarian cancer. 
     
     
         23 . The method of  claim 18 , wherein the method further comprises administering an additional anti-cancer agent selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, epirubicin, cyclophosphamide, capecitabine, 5-fluorouracil, vinorelbine, trastuzumab, or bevacizumab.